An Ignoble Experiment

‘CHIP’ping away at clonal hematopoiesis

D C Link and M J Walter

Leukemia 2016 30: 1633-1635; advance online publication, June 17, 2016; 10.1038/leu.2016.130

Commentary on: ‘Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia’

C A Schiffer

Leukemia 2016 30: 1636-1637; advance online publication, June 10, 2016; 10.1038/leu.2016.141

Reviews

The concept of treatment-free remission in chronic myeloid leukemia OPEN

S Saußele, J Richter, A Hochhaus and F-X Mahon

Leukemia 2016 30: 1638-1647; advance online publication, May 2, 2016; 10.1038/leu.2016.115

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia OPEN

J L Steegmann, M Baccarani, M Breccia, L F Casado, V García-Gutiérrez, A Hochhaus, D-W Kim, T D Kim, H J Khoury, P Le Coutre, J Mayer, D Milojkovic, K Porkka, D Rea, G Rosti, S Saussele, R Hehlmann and R E Clark

Leukemia 2016 30: 1648-1671; advance online publication, April 28, 2016; 10.1038/leu.2016.104

Original Articles

ACUTE MYELOID LEUKEMIA

Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia OPEN

V Madan, P Shyamsunder, L Han, A Mayakonda, Y Nagata, J Sundaresan, D Kanojia, K Yoshida, S Ganesan, N Hattori, N Fulton, K-T Tan, T Alpermann, M-C Kuo, S Rostami, J Matthews, M Sanada, L-Z Liu, Y Shiraishi, S Miyano, E Chendamarai, H-A Hou, G Malnassy, T Ma, M Garg, L-W Ding, Q-Y Sun, W Chien, T Ikezoe, M Lill, A Biondi, R A Larson, B L Powell, M Lübbert, W J Chng, H-F Tien, M Heuser, A Ganser, M Koren-Michowitz, S M Kornblau, H M Kantarjian, D Nowak, W-K Hofmann, H Yang, W Stock, A Ghavamzadeh, K Alimoghaddam, T Haferlach, S Ogawa, L-Y Shih, V Mathews and H P Koeffler

Leukemia 2016 30: 1672-1681; advance online publication, April 11, 2016; 10.1038/leu.2016.69

ACUTE LYMPHOBLASTIC LEUKEMIA

CDKN2A-independent role of BMI1 in promoting growth and survival of Ph+ acute lymphoblastic leukemia

S A Mariani, V Minieri, M De Dominici, I Iacobucci, L F Peterson and B Calabretta

Leukemia 2016 30: 1682-1690; advance online publication, April 5, 2016; 10.1038/leu.2016.70

Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia OPEN

D Pal, H J Blair, A Elder, K Dormon, K J Rennie, D J L Coleman, J Weiland, K S Rankin, A Filby, O Heidenreich and J Vormoor

Leukemia 2016 30: 1691-1700; advance online publication, May 25, 2016; 10.1038/leu.2016.79

CHRONIC MYELOPROLIFERATIVE NEOPLASMS

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis OPEN

C N Harrison, A M Vannucchi, J-J Kiladjian, H K Al-Ali, H Gisslinger, L Knoops, F Cervantes, M M Jones, K Sun, M McQuitty, V Stalbovskaya, P Gopalakrishna and T Barbui on behalf of the COMFORT-II Investigators

Leukemia 2016 30: 1701-1707; advance online publication, May 23, 2016; 10.1038/leu.2016.148

MOLECULAR TARGETS FOR THERAPY

Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate

A Chaturvedi, M M Araujo Cruz, N Jyotsana, A Sharma, R Goparaju, A Schwarzer, K Görlich, R Schottmann, E A Struys, E E Jansen, C Rohde, C Müller-Tidow, R Geffers, G Göhring, A Ganser, F Thol and M Heuser

Leukemia 2016 30: 1708-1715; advance online publication, April 11, 2016; 10.1038/leu.2016.71

IMMUNOTHERAPY

Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade

H Suen, R Brown, S Yang, C Weatherburn, P J Ho, N Woodland, N Nassif, P Barbaro, C Bryant, D Hart, J Gibson and D Joshua

Leukemia 2016 30: 1716-1724; advance online publication, April 22, 2016; 10.1038/leu.2016.84

TRANSCRIPTIONAL CONTROL AND SIGNAL TRANSDUCTION, CELL CYCLE

Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3⁺-mediated leukemic phenotype

T A Müller, R Grundler, R Istvanffy, M Rudelius, L Hennighausen, A L Illert and J Duyster

Leukemia 2016 30: 1725-1733; advance online publication, April 5, 2016; 10.1038/leu.2016.72

ANIMAL MODELS

GPR56 contributes to the development of acute myeloid leukemia in mice

D Daria, N Kirsten, A Muranyi, M Mulaw, S Ihme, A Kechter, M Hollnagel, L Bullinger, K Döhner, H Döhner, M Feuring-Buske and C Buske

Leukemia 2016 30: 1734-1741; advance online publication, April 11, 2016; 10.1038/leu.2016.76

Letters to the Editor

Donor cell-derived hematological malignancy: a survey by the Japan Society for Hematopoietic Cell Transplantation

M Kato, T Yamashita, R Suzuki, K Matsumoto, H Nishimori, S Takahashi, K Iwato, C Nakaseko, T Kondo, K Imada, F Kimura, T Ichinohe, Y Hashii, K Kato, Y Atsuta, S Taniguchi and T Fukuda

Leukemia 2016 30: 1742-1745; advance online publication, February 12, 2016; 10.1038/leu.2016.23

Gaq signaling is required for the maintenance of MLL-AF9-induced acute myeloid leukemia

J R Lynch, H Yi, D A Casolari, F Voli, E Gonzales-Aloy, T K Fung, B Liu, A Brown, T Liu, M Haber, M D Norris, I D Lewis, C W E So, R J D’Andrea and J Y Wang

Leukemia 2016 30: 1745-1748; advance online publication, February 9, 2016; 10.1038/leu.2016.24

Interleukin-15 deficiency promotes the development of T-cell acute lymphoblastic leukemia in non-obese diabetes mice with severe combined immunodeficiency

D Bobbala, R Kandhi, X Chen, M Mayhue, E Bouchard, J Yan, H Knecht, F Barabé, S Ramanathan and S Ilangumaran

Leukemia 2016 30: 1749-1752; advance online publication, February 15, 2016; 10.1038/leu.2016.28

Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia

I Alvarez-Twose, P Martínez-Barranco, J Gotlib, A García-Montero, J M Morgado, M Jara-Acevedo, J D Merker, F J Peñalver, A Matito, Y Hou, L Sánchez-Muñoz, A Mayado, M Mollejo, L Escribano and A Orfao

Leukemia 2016 30: 1753-1756; advance online publication, February 15, 2016; 10.1038/leu.2016.30

Clonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation

P Hirsch, A C Mamez, R Belhocine, S Lapusan, R Tang, L Suner, D Bories, C Marzac, F Fava, O Legrand, M Mohty, L Douay and F Delhommeau

Leukemia 2016 30: 1756-1759; advance online publication, March 1, 2016; 10.1038/leu.2016.31

Thrombopoietin receptor is required for the oncogenic function of CALR mutants OPEN

H Nivarthi, D Chen, C Cleary, B Kubesova, R Jäger, E Bogner, C Marty, C Pecquet, W Vainchenker, S N Constantinescu and R Kralovics

Leukemia 2016 30: 1759-1763; advance online publication, February 17, 2016; 10.1038/leu.2016.32

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab OPEN

C L Freeman, M Dixon, R Houghton, K-A Kreuzer, G Fingerle-Rowson, M Herling, K Humphrey, S Böttcher, C S de Costa, V Iglesias, S Stilgenbauer, J Gribben, M Hallek and V Goede

Leukemia 2016 30: 1763-1766; advance online publication, March 4, 2016; 10.1038/leu.2016.41

Familial associations of monoclonal gammopathy of unknown significance with autoimmune diseases

K Hemminki, A Försti, K Sundquist, J Sundquist and X Li

Leukemia 2016 30: 1766-1769; advance online publication, February 29, 2016; 10.1038/leu.2016.43

Harmonemia: a universal strategy for flow cytometry immunophenotyping—A European LeukemiaNet WP10 study

F Lacombe, E Bernal, D Bloxham, S Couzens, M G D Porta, U Johansson, W Kern, M Macey, T Matthes, R Morilla, A Paiva, C Palacio, F Preijers, R Ratei, S Siitonen, K Allou, A Porwit and M C Béné

Leukemia 2016 30: 1769-1772; advance online publication, February 29, 2016; 10.1038/leu.2016.44

JAK2^V617F allele burden ≥ 50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy

G Barosi, C Klersy, L Villani, E Bonetti, P Catarsi, V Poletto, R Campanelli, S Impera, R Latagliata, G Viarengo, A Carolei, M Massa, M Musso, A Crescimanno, R P Gale and V Rosti

Leukemia 2016 30: 1772-1775; advance online publication, February 29, 2016; 10.1038/leu.2016.45

Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin

T Balligand, Y Achouri, C Pecquet, I Chachoua, H Nivarthi, C Marty, W Vainchenker, I Plo, R Kralovics and S N Constantinescu

Leukemia 2016 30: 1775-1778; advance online publication, February 29, 2016; 10.1038/leu.2016.47

Prediction of CR following a second course of ‘7+3’ in patients with newly diagnosed acute myeloid leukemia not in CR after a first course

M Othus, S Mukherjee, M A Sekeres, J Godwin, S Petersdorf, F R Appelbaum, H Erba and E Estey

Leukemia 2016 30: 1779-1780; advance online publication, February 29, 2016; 10.1038/leu.2016.48

Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia

T Büchner, U O Krug, R Peter Gale, A Heinecke, M C Sauerland, C Haferlach, S Schnittger, T Haferlach, C Müller-Tidow, M Stelljes, R M Mesters, H L Serve, J Braess, K Spiekermann, P Staib, A Grüneisen, A Reichle, L Balleisen, H Eimermacher, A Giagounidis, H Rasche, E Lengfelder, D Görlich, A Faldum, W Köpcke, R Hehlmann, B J Wörmann, W E Berdel and W Hiddemann

Leukemia 2016 30: 1781-1784; advance online publication, March 11, 2016; 10.1038/leu.2016.54

The catalytic activity of TET2 is essential for its myeloid malignancy-suppressive function in hematopoietic stem/progenitor cells

Z Zhao, S Chen, X Zhu, F Pan, R Li, Y Zhou, W Yuan, H Ni, F-C Yang and M Xu

Leukemia 2016 30: 1784-1788; advance online publication, March 8, 2016; 10.1038/leu.2016.56

CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR axis

M Braun, M Qorraj, M Büttner, F A Klein, D Saul, M Aigner, W Huber, A Mackensen, R Jitschin and D Mougiakakos

Leukemia 2016 30: 1788-1792; advance online publication, March 8, 2016; 10.1038/leu.2016.58

Correspondence

High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort

S Goel, J Hall, K Pradhan, C Hirsch, B Przychodzen, A Shastri, I Mantzaris, M Janakiram, R Battini, N Kornblum, O Derman, K Gritsman, J Al-Hafidh, Y Wang, B Halmos, U Steidl, J P Maciejewski, I Braunschweig and A Verma

Leukemia 2016 30: 1793-1795; advance online publication, April 29, 2016; 10.1038/leu.2016.74

Effectiveness of azacitidine in higher-risk myelodysplastic syndromes

A G Dinmohamed, Y van Norden, A A van de Loosdrecht and M Jongen-Lavrencic

Leukemia 2016 30: 1795-1796; advance online publication, May 20, 2016; 10.1038/leu.2016.117

How many cycles of 7+3 and for whom?

Y Ofran and J M Rowe

Leukemia 2016 30: 1796-1797; advance online publication, May 13, 2016; 10.1038/leu.2016.86

Do adults aged 70 years or older with acute myeloid leukemia benefit from allogeneic hematopoietic cell transplantation?

A Rashidi, J F DiPersio, P Westervelt, R Vij, C N Abboud and R Romee

Leukemia 2016 30: 1797-1799; advance online publication, May 27, 2016; 10.1038/leu.2016.99

PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP

K Lontos

Leukemia 2016 30: 1799-1800; advance online publication, May 17, 2016; 10.1038/leu.2016.103

Response to ‘PET after response to R-CHOP in primary mediastinal large B-cell lymphoma’

TP Vassilakopoulos, S Papageorgiou, GA Pangalis, S Chatziioannou, MK Angelopoulou, P Panayiotidis, K Konstantopoulos and P Rondogianni

Leukemia 2016 30: 1800-1801; advance online publication, June 3, 2016; 10.1038/leu.2016.109

IKZF1 deletion is enriched in pediatric B-cell precursor acute lymphoblastic leukemia patients showing prednisolone resistance

T Imamura, M Yano, D Asai, A Moriya-Saito, S-I Suenobu, D Hasegawa, T Deguchi, Y Hashii, H Kawasaki, H Hori, K Yumura-Yagi, J Hara, K Horibe and A Sato

Leukemia 2016 30: 1801-1803; advance online publication, May 20, 2016; 10.1038/leu.2016.128

Decrease in total protein level of Bruton’s tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes

F Cervantes-Gomez, V Kumar Patel, P Bose, M J Keating and V Gandhi

Leukemia 2016 30: 1803-1804; advance online publication, May 20, 2016; 10.1038/leu.2016.129